Notice2022-12922
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 16, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 116 (Thursday, June 16, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 116 (Thursday, June 16, 2022)]
[Notices]
[Pages 36338-36339]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-12922]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483, or
<a href="/cdn-cgi/l/email-protection#3545504150471b41405b52755b5c5d1b525a43"><span class="__cf_email__" data-cfemail="7404110011065a00011a13341a1d1c5a131b02">[email protected]</span></a>. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed
Confidential
[[Page 36339]]
Disclosure Agreement will be required to receive copies of unpublished
patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows:
Beta Globin Mimetic Peptides and Their Use
Description of Technology
Feedback vasodilation by endothelium-derived nitric oxide (NO) is
under the regulation of globins. Inventors discovered that not only the
alpha globin but also the beta globin subunits of hemoglobin are
expressed in the human artery wall, with beta globin interacting
directly with endothelial nitric oxide synthase (eNOS). This discovery
of tetrameric hemoglobin binding to eNOS has led inventors to develop
novel mimetic peptides that disrupt the binding of beta globin to eNOS,
diminishing the ability of hemoglobin to restrict NO release and
thereby enhancing NO-mediated feedback vasodilation. These agents can
be used to increase NO signaling from endothelial cells and thus
inhibit, prevent, or reverse vasoconstriction.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Novel peptides to treat vascular diseases characterized by
vasoconstriction, excess alpha adrenergic signaling, or insufficient
nitric oxide signaling. Applications could range from cerebral
vasospasm to pulmonary hypertension to chronic kidney disease to
transfusion medicine to erectile dysfunction to exercise physiology.
Competitive Advantages
<bullet> New pathway for regulation of vasoconstriction/
vasodilation.
<bullet> Enhancement of NO release at the junction between the
endothelial cell and smooth muscle cell may provide greater potency and
fewer off-target effects than other forms of NO delivery.
Development Stage: Peptides have been tested in human and canine
arteries ex vivo.
Inventors: Drs. Hans Ackerman, Steven Brooks, Phillip Cruz, all of
NIAID.
Publications: ``Hemoglobin Interacts with Endothelial Nitric Oxide
Synthase to Regulate Vasodilation in Human Resistance Arteries'',
<a href="https://doi.org/10.1101/2021.04.06.21255004">https://doi.org/10.1101/2021.04.06.21255004</a>.
Intellectual Property: HHS Reference No. E-060-2022-0-US-01--U.S.
Provisional Application No. 63/328,615, filed April 7, 2022.
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483, or <a href="/cdn-cgi/l/email-protection#a0d0c5d4c5d28ed4d5cec7e0cec9c88ec7cfd6"><span class="__cf_email__" data-cfemail="6313061706114d17160d04230d0a0b4d040c15">[email protected]</span></a>.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize the invention. For collaboration
opportunities, please contact Peter Tung at 240-669-5483;
<a href="/cdn-cgi/l/email-protection#4535203120376b31302b22052b2c2d6b222a33"><span class="__cf_email__" data-cfemail="28584d5c4d5a065c5d464f68464140064f475e">[email protected]</span></a>.
Dated: June 9, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-12922 Filed 6-15-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 16, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.